## Danish Medicines Agency

CERTIFICATE NUMBER: DK IMP 10000944

## CERTIFICATE OF GMP COMPLIANCE OF A MANUFACTURER

## Part 1

Issued following an inspection in accordance with

Art. 63 of Regulation (EU) 536/2014

The competent authority of Denmark confirms the following:

The manufacturer: Solural Pharma ApS

Site address: Energivej 42, Ballerup, 2750, Denmark, GPS: 55.724853, 12.373501 OMS Organisation Id. / OMS Location Id.: ORG-100006163 / LOC-100010601

Has been inspected under the national inspection programme in accordance with Art. 61 of Regulation (EU) No 536/2014.

From the knowledge gained during inspection of this manufacturer, the latest of which was conducted on 2024-01-31, it is considered that it complies with:

• The principles and guidelines of Good Manufacturing Practice laid down in Directive (EU) 2017/1572 and/or Commission Delegated Regulation (EU) 2017/1569, as reflected by the product categories stated in Part 2.3

This certificate reflects the status of the manufacturing site at the time of the inspection noted above and should not be relied upon to reflect the compliance status if more than three years have elapsed since the date of that inspection. However, this period of validity may be reduced or extended using regulatory risk management principles by an entry in the Restrictions or Clarifying remarks field. Updates to restrictions or clarifying remarks can be identified through the EudraGMDP website (http://eudragmdp.ema.europa.eu/). This certificate is valid only when presented with all pages and both Parts 1 and 2.

The authenticity of this certificate may be verified in EudraGMDP. If it does not appear, please contact the issuing authority.

Signatory: Confidential

<sup>&</sup>lt;sup>1</sup>The certificate referred to in paragraph Art. 15 of Directive 2001/20/ECis also applicable to importers.

<sup>&</sup>lt;sup>2</sup>Guidance on the interpretation of this template can be found in the Interpretation of the Union format for GMP certificate.

These requirements fulfil the GMP recommendations of WHO.

## Part 2

Human Investigational Medicinal Products

	NUFACTURING OPERATIONS	
1.2	Non-sterile products	
	1.2.1 Non-sterile products (processing operations for the following dosage forms)	
		1.2.1.1 Capsules, hard shell
		1.2.1.5 Liquids for external use
		1.2.1.6 Liquids for internal use
		1.2.1.8 Other solid dosage forms: Powders and granules(en)
		1.2.1.9 Pressurised preparations
		1.2.1.11 Semi-solids
		1.2.1.13 Tablets
	1.2.2	Batch certification
1.5	Packaging	
	1.5.1	Primary Packaging
		1.5.1.1 Capsules, hard shell
		1.5.1.5 Liquids for external use
		1.5.1.6 Liquids for internal use
		1.5.1.8 Other solid dosage forms: Powder and granules(en)
		1.5.1.9 Pressurised preparations
		1.5.1.11 Semi-solids
		1.5.1.13 Tablets
	1.5.2	Secondary packaging
1.6	Quality control testing	
	1.6.3	Chemical/Physical

2024-04-30

Name and signature of the authorised person of the Competent Authority of Denmark

Confidential Danish Medicines Agency Tel: Confidential

Fax. Confidential